Publication:
Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling

Thumbnail Image

Date

2012

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier BV
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Mekhoubad, Shila, Christoph Bock, A. Sophie de Boer, Evangelos Kiskinis, Alexander Meissner, and Kevin Carl Eggan. 2012. “Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling.” Cell Stem Cell 10 (5): 595–609.

Research Data

Abstract

Although distinct human induced pluripotent stem cell (hiPSC) lines can display considerable epigenetic variation, it has been unclear whether such variability impacts their utility for disease modeling. Here, we show that although low-passage female hiPSCs retain the inactive X chromosome of the somatic cell they are derived from, over time in culture they undergo an “erosion” of X chromosome inactivation (XCI). This erosion of XCI is characterized by loss of XIST expression and foci of H3-K27-trimethylation, as well as transcriptional derepression of genes on the inactive X that cannot be reversed by either differentiation or further reprogramming. We specifically demonstrate that erosion of XCI has a significant impact on the use of female hiPSCs for modeling Lesch-Nyhan syndrome. However, our finding that most genes subject to XCI are derepressed by this erosion of XCI suggests that it should be a significant consideration when selecting hiPSC lines for modeling any disease.

Description

Keywords

Terms of Use

Metadata Only

Endorsement

Review

Supplemented By

Referenced By

Related Stories